Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation after CABG

Principal Investigator

Alexander Iribarne

Study Number

SF19164

Summary

The purpose of the research is to compare two commonly used treatment strategies for managing atrial fibrillation after cardiac surgery. Atrial fibrillation (AF) is the most common irregular heartbeat that occurs in some patients after they undergo coronary artery bypass surgery. It can develop when the upper chambers of the heart (atria) produces a disorganized electrical activity, which then causes your heart to beat irregularly. Patients who have this heart beat irregularity are at a higher risk of developing blood clots in the heart, which can cause a stroke, and result in death. There are two classes of drugs for preventing blood clots: antiplatelet drugs and anticoagulants. Antiplatelet drugs prevent clots from forming and growing by stopping blood cell fragments, called platelets, from clumping together. Anticoagulants work differently. They affect the reaction of the clotting proteins in your blood, so that your blood is ?thinner? and less likely to form a clot. These drugs can also cause you to bleed more easily. This study aims to determine which treatment works best in patients who develop AF after coronary artery bypass surgery.

Phase

Phase IV

Contact

Prezley Duncan

Available at the following location(s)

  • Lebanon

View more details at ClinicalTrials.gov

Do you need help with some of the labels on this page?
Read our glossary of terms

0